Bimekizumab efficacy in high-impact areas for patients with moderate to severe plaque psoriasis: Pooled results through two years from the BE SURE and BE RADIANT phase 3 trials

**Objectives**
To evaluate scalp, nail, and palmar/plantar (p/p) outcomes over 2 years in patients with moderate to severe plaque psoriasis treated with two different bimekizumab (BKZ) maintenance dosing regimens.

**Introduction**
Plaque psoriasis affecting the scalp, nails, palms, and soles can cause significant physical impairment and negative impact of quality of life therefore, clearance of psoriasis in these high-impact areas is of substantial clinical interest. High levels of complete clearance in high-impact areas after 1 year of BKZ treatment have been reported.

**Materials and Methods**
Data were pooled from over 2 years from the 1-year BE SURE phase 3 trial (NCT03536884), incorporating the first year of ongoing open-label extension OLE (Cleveland, Case Western Reserve University, Cleveland, Ohio, USA; 6UCB Pharma, Slough, UK; 7UCB Pharma, Monheim, Germany; 8Amgen, Thousand Oaks, CA, USA; 9Psoriasis Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Germany).

Data are reported using modified non-responder imputation (mNRI), and data are presented for patients who received BKZ every 4 weeks (BE BRIGHT trial) or every 8 weeks (BE RADIANT trial) through Week 56. Patients randomised to 4-weekly treatment who achieved PASI 90 at Week 52 received open-label treatment for an additional 2 years (BE BRIGHT OLE), while those randomised to 8-weekly treatment at Week 52 were randomised to continue 8-weekly treatment or switch to 4-weekly treatment (BE RADIANT OLE).

**Results**
Baseline characteristics for patients included in this analysis are presented in Table 1. Conclusions are provided in the Discussion section.

**Conclusions**
Complete and sustained clearance of scalp, nail, or palmar/plantar psoriasis over 2 years (mNRI, NRI, OC).

**Table 1** Baseline characteristics

<table>
<thead>
<tr>
<th>Age (years), mean ± SD</th>
<th>45.6 ± 13.5</th>
<th>45.0 ± 14.3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male (n, %)</td>
<td>210 (69.1)</td>
<td>225 (67.7)</td>
</tr>
<tr>
<td>Caucasian (n, %)</td>
<td>265 (87.5)</td>
<td>298 (92.3)</td>
</tr>
<tr>
<td>Weight (kg), mean ± SD</td>
<td>91.8 ± 21.0</td>
<td>90.0 ± 21.1</td>
</tr>
<tr>
<td>PASI, mean ± SD</td>
<td>18.4 ± 13.0</td>
<td>18.0 ± 12.2</td>
</tr>
</tbody>
</table>

**Figure 1** Study design (included patients)

**Figure 2** Tools used to assess disease severity

**Figure 3** Complete regional clearance of scalp, nail, or palmar/plantar psoriasis over 2 years (mNRI, NRI, OC)

Joseph F. Merola,1 Alice B. Gottlieb,2 Akimichi Morita,3 Jose-Manuel Carrascosa,4 Boni Elewski,5 Nicola Tit',5 Susanne Wiegartz,5 Cristina Wixted,2 Ulrich Mrowietz3

**Disclosure**
Complete and sustained clearance of scalp, nail, or palmar/plantar psoriasis achieved at a high proportion of BKZ-treated patients over two years, regardless of dosing regimen.

To receive a copy of this poster, visit the UCB Pharma website.

**References**
1. Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts, USA; 2Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 4Universitat Autònoma de Barcelona, Barcelona, Spain; 5Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio, USA; 6UCB Pharma, Slough, UK; 7UCB Pharma, Monheim, Germany; 8Amgen, Thousand Oaks, CA, USA; 9Psoriasis Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Germany.

**Author Contributions**
Substantial contributions to study conception/design, or acquisition/analysis/interpretation of data: JFM, ABG, AM, JMC, BE, NT, SW, KW, UM. Final approval of the publication: JFM, ABG, AM, JMC, BE, NT, SW, KW, UM. All costs associated with development of this poster were funded by UCB Pharma.